Eli Lilly: Dominance Has A Price

Eli Lilly and Company has been criticized for its high prices and aggressive marketing tactics for its diabetes drug, Trulicity.

The company's shares have been performing well, but analysts warn that its dominance in the diabetes market may be at risk.

While this news may not directly impact seafarers, it could have broader economic implications that could indirectly affect the shipping industry.